Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.
BMJ Case Rep
; 20162016 Jun 17.
Article
em En
| MEDLINE
| ID: mdl-27317760
ABSTRACT
We report a case of a 60-year-old man who was referred to a palliative care clinic with monoclonal gammopathy of undetermined significance (MGUS)-associated neuropathy, responding to a therapeutic trial of warfarin. Electromyography showed distal symmetric sensory axonal neuropathy. The patient reported having had improvement of his neuropathic symptoms while taking warfarin postoperatively for thromboprophylaxis 1â
year prior, and recurrence of his symptoms after the warfarin was discontinued. The patient was rechallenged with a trial of warfarin, targeting an international normalised ratio of 1.5-2.0. His pain scores decreased from 5/10 to 3/10 at 1â
month and symptom improvement was maintained through 24â
months of follow-up. Warfarin had a remarkable impact on our patient's symptoms and quality of life. The mechanisms mediating the symptomatic benefit with warfarin are unclear; however, a placebo effect is unlikely. Further studies may help guide the use of warfarin for MGUS-associated neuropathy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Varfarina
/
Gamopatia Monoclonal de Significância Indeterminada
/
Doenças do Sistema Nervoso Periférico
/
Anticoagulantes
Tipo de estudo:
Clinical_trials
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
BMJ Case Rep
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos